Use of Hericium erinaceus as a potential therapeutic of mental disorders: a systematic review
DOI:
https://doi.org/10.25118/2763-9037.2023.v13.443Keywords:
Hericium erinaceus, mental disorders, cognitive dysfunctionAbstract
Introduction: Hericium erinaceus (HE), often known as Lion's Mane, is an edible fungus that has been extensively explored for its many functions. The use of this mushroom in traditional Chinese medicine dates back many years, and it is now being tested in the treatment of cognitive decline and Alzheimer's disease, and mental diseases like depression, anxiety, schizophrenia. Methods: We followed 2020 PRISMA statement for systematic reviews. The three selected databases were Worldcat®, Cochrane Library®, and PubMed®. On March 7, 2022, a search for articles was conducted. The search sources' descriptions were Hericium erinaceus AND (mental disorders OR cognitive impairment OR depression OR anxiety). "English" was the sole filter applied to the data sources. Results: Three Japanese randomized double-blind controlled trials were included in the review. Although the data demonstrated that HE can be useful in treating symptoms of cognitive impairment and moderate cognitive impairment, it was not effective in treating depression/anxiety symptoms. Conclusions: More studies are needed in countries besides Japan, lasting at least 12 weeks, since shorter periods do not demonstrate significant improvement of symptoms. Incorporating HE into a patient's daily diet may produce favorable benefits by alleviating cognitive decline.
Downloads
Metrics
References
Fava GA, Tomba E, Bech P. Clinical pharmacopsychology: conceptual foundations and emerging tasks. Psychother Psychosom. 2017;86(3):134-40. https://doi.org/10.1159/000458458 PMID:28490035
Nutt D, Erritzoe D, Carhart-Harris R. Psychedelic psychiatry's brave new world. Cell. 2020;181(1):24-8. https://doi.org/10.1016/j.cell.2020.03.020 - PMID:32243793
Rucker JJH, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. 2018;142:200-18. https://doi.org/10.1016/j.neuropharm.2017.12.040 PMID:29284138
Chong PS, Fung ML, Wong KH, Lim LW. Therapeutic potential of Hericium erinaceus for depressive disorder. Int J Mol Sci. 2019;21(1):163. https://doi.org/10.3390/ijms21010163 PMID:31881712 - PMCID:PMC6982118
Inanaga K. Amycenone, a nootropic found in Hericium erinaceum. Personal Med Universe. 2012;1(1):13-7. https://doi.org/10.1016/j.pmu.2012.05.003
Ryu S, Kim HG, Kim JY, Kim SY, Cho KO. Hericium erinaceus extract reduces anxiety and depressive behaviors by promoting hippocampal neurogenesis in the adult mouse brain. J Med Food. 2018;21(2):174-80. https://doi.org/10.1089/jmf.2017.4006 PMID:29091526
Kuo HC, Lu CC, Shen CH, Tung SY, Hsieh MC, Lee KC, Lee LY, Chen CC, Teng CC, Huang WS, Chen TC, Lee KF. Hericium erinaceus mycelium and its isolated erinacine A protection from MPTP-induced neurotoxicity through the ER stress, triggering an apoptosis cascade. J Transl Med. 2016;14:78. https://doi.org/10.1186/s12967-016-0831-y - PMID:26988860 - PMCID:PMC4797317
Tsai-Teng T, Chin-Chu C, Li-Ya L, Wan-Ping C, Chung-Kuang L, Chien-Chang S, Chi-Ying HF, Chien-Chih C, Shiao YJ. Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer's disease-related pathologies in APPswe/PS1dE9 transgenic mice. J Biomed Sci. 2016;23:49. https://doi.org/10.1186/s12929-016-0266-z - PMID:27350344 - PMCID:PMC4924315
Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K. Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomed Res. 2019;40(4):125-31. https://doi.org/10.2220/biomedres.40.125 - PMID:31413233
Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, McKenzie JE. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https://doi.org/10.1136/bmj.n160 - PMID:33781993 PMCID:PMC8005925
Nagano M, Shimizu K, Kondo R, Hayashi C, Sato D, Kitagawa K, Ohnuki K. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res. 2010;31(4):231-7. https://doi.org/10.2220/biomedres.31.231 - PMID:20834180
Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009;23(3):367-72. https://doi.org/10.1002/ptr.2634 - PMID:18844328
Imai Y, Hasegawa K. The revised Hasegawa's Dementia Scale (HDS-R): evaluation of its usefulness as a screening test for dementia. J Hong Kong Coll Psychiatr. 1994; 4:20-24. https://www.easap.asia/index.php/advanced-search/item/503-v4n2-9402-p20-24
Kohler O, Krogh J, Mors O, Benros ME. Inflammation in depression and the potential for anti-inflammatory treatment. Curr Neuropharmacol. 2016;14(7):732-42. https://doi.org/10.2174/1570159X14666151208113700 PMID:27640518 - PMCID:PMC5050394
Binder DK, Scharfman HE. Brain-derived neurotrophic factor. Growth Factors. 2004;22(3):123-31. https://doi.org/10.1080/08977190410001723308 - PMID:15518235 - PMCID:PMC2504526
Troubat R, Barone P, Leman S, Desmidt T, Cressant A, Atanasova B, Brizard B, El Hage W, Surget A, Belzung C, Camus V. Neuroinflammation and depression: a review. Eur J Neurosci. 2021;53(1):151-71. https://doi.org/10.1111/ejn.14720 - PMID:32150310
Wong KH, Naidu M, David RP, Bakar R, Sabaratnam V. Neuroregenerative potential of lion's mane mushroom, Hericium erinaceus (Bull.: Fr.) Pers. (higher Basidiomycetes), in the treatment of peripheral nerve injury. Int J Med Mushrooms. 2012;14(5):427-46. https://doi.org/10.1615/IntJMedMushr.v14.i5.10 PMID:23510212
Li IC, Lee LY, Tzeng TT, Chen WP, Chen YP, Shiao YJ, Chen CC. Neurohealth properties of Hericium erinaceus mycelia enriched with erinacines. Behav Neurol. 2018;2018:5802634. https://doi.org/10.1155/2018/5802634 - PMID:29951133 PMCID:PMC5987239
Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O’Donnell K, Owens LT, Podrebarac S, Rotrosen J, Toningan JS, Worth L. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79(10):953-62. https://doi.org/10.1001/jamapsychiatry.2022.2096 - PMID:36001306 - PMCID:PMC9403854
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Pietra McDonnel Matheus Cortonesi, Laura Fogaça de Almeida, Rafael Monteiro Tancredi Pinheiro, Cintia de Azevedo-Marques Périco, João Maurício Castaldelli-Maia
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria allows the author (s) to keep their copyrights unrestricted. Allows the author (s) to retain their publication rights without restriction. Authors should ensure that the article is an original work without fabrication, fraud or plagiarism; does not infringe any copyright or right of ownership of any third party. Authors should also ensure that each one complies with the authorship requirements as recommended by the ICMJE and understand that if the article or part of it is flawed or fraudulent, each author shares responsibility.
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) - Debates em Psiquiatria is governed by the licencse CC-By-NC
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
